Clinical Trial: A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264816) titled 'A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC' on Nov. 24.

Brief Summary: This trial is a multicenter, open-label, Phase II clinical study to explore the efficacy and safety of BL-M07D1 in combination with pembrolizumab in patients with locally advanced or metastatic HER2-overexpressing non-squamous non-small cell lung cancer.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Non-squamous Non-small Cell Lung Cancer

Intervention: DRUG: BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks...